Adar1 Capital Management, LLC Summit Therapeutics Inc. Transaction History
Adar1 Capital Management, LLC
- $652 Billion
- Q2 2025
A detailed history of Adar1 Capital Management, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Adar1 Capital Management, LLC holds 12,000 shares of SMMT stock, worth $250,799. This represents 0.04% of its overall portfolio holdings.
Number of Shares
12,000
Previous 100,000
88.0%
Holding current value
$250,799
Previous $1.93 Billion
86.76%
% of portfolio
0.04%
Previous 0.36%
Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
260Shares Held
90.4MCall Options Held
4.71MPut Options Held
3.17M-
Baker Bros. Advisors LP New York, NY33.7MShares$705 Million7.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.67MShares$181 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$165 Million0.0% of portfolio
-
State Street Corp Boston, MA4.02MShares$84 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.91MShares$81.6 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $4.21B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...